Chapter 1 - Hydroxychloroquine Archives • Children's Health Defense

1

Bill & Melinda Gates Foundation, “2018 Form 990, Attachment C,” page 4, Cause IQ (2018).

2

U.S. Food & Drug Administration, “Emergency Use Authorization of Medical Products and Related Authorities,” (Jan. 2017).

3

Jonathan Saltzman, “US Government Has Invested $6 Billion In Moderna’s COVID-19 Vaccine,” STAT News (Apr. 30, 2021).

4

Bob Herman, “NIH-Moderna Confidential Disclosure Agreement,” AXIOS (Nov. 6, 2015).

5

Zain Rizvi, “The NIH Vaccine,” Public Citizen (Jun. 25, 2020).

6

Legal Information Institute, “15 U.S. Code § 3710c – Distribution of royalties received by Federal agencies,” Cornell Law School.

7

Marisa Taylor and Aram Roston, “Pressed by Trump, U.S. pushed unproven coronavirus treatment guidance,” Reuters (Apr. 4, 2020).

8

World Health Organization, “Unedited Report of the 18th Expert Committee on the Selection and Use of Essential Medicines,” (Mar. 21-25, 2011).

9

Concordia Pharmaceuticals Inc, “PLAQUENIL® HYDROXYCHLOROQUINE SULFATE TABLETS, USP,” (Jan. 2017).

10

Stella Immanuel, MD, Let America Live: Exposing The Hidden Agenda Behind The 2020 Pandemic: My Journey, Ch. 1 (Charisma House 2021).

11

Centers for Disease Control and Prevention, “Medicines for the Prevention of Malaria While Traveling Hydroxychloroquine (Plaquenil™).”

12

Peter A. McCullough, MD, “Why doctors and researchers need access to hydroxychloroquine,” The Hill (Aug. 7, 2020).

13

Els Keyaerts, et al., “In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine,” Biochemical And Biophysical Research Communications 323 no. 1 (2004): 264-8. doi:10.1016/j.bbrc.2004.08.085.

14

Els Keyaerts, et al., “In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine,” Biochemical And Biophysical Research Communications 323 no. 1 (2004): 264-8, doi:10.1016/j.bbrc.2004.08.085.

15

Martin J. Vincent et al, “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread,” Virology Journal Vol. 2 (Aug 22, 2005):69.

16

Julie Dyall, et al, “Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection,” Antimicrobial Agents And Chemotherapy Vol. 58, 8 (2014): 4885-93.

17

Adriaan H. de Wilde et al., “Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture,” Asm Journals Antimicrobial Agents And Chemotherapy 58 no. 8 (2014): 4875-4884.

18

Yi Su et al, “Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China,” Bioscience Trends 14 no. 6 (Jan 23, 2021):408-414.

19

Jean-Christophe Lagier et al, “Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis,” Travel Medicine And Infectious Disease 36: 101791 (Jul-Aug,2020).

20

Saja H. Almazrou, et al., “Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study,” Saudi Pharmaceutical Journal 28 no. 12 (Dec 2020): 1877–1882.

21

Majid Mokhtaria et al, “Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting,” International Immunopharmacology 96: 107636 (Jul., 2021).

22

The COVID-19 RISK and Treatments (CORIST) Collaboration, “Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study,” European Journal Of Internal Medicine 82 (Dec 1, 2020): 38-47.

23

Awadhesh Kumar Singh et al, “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries,” Diabetes & Metabolic Syndrome: Clinical Research And Reviews 14 no. 3 (May-Jun, 2020):241-246.

24

Alyssa Paolicelli, “Drug Combo with Hydroxychloroquine Promising: NYU Study,” Spectrum News Ny1 (May 20, 2021, 7:18 AM).

25

Roland Derwand, Martin Scholz and Vladimir Zelenko, “COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study,” International Journal of Antimicrobial Agents 56(6):106214 (Dec 2020).

26

Samia Arshad, “Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19,” International Journal of Infectious Diseases 97 (Aug., 2020):396-403.

27

Fabricio Souza Neves, “Correlation of the rise and fall in COVID-19 cases with the social isolation index and early outpatient treatment with hydroxychloroquine and chloroquine in the state of Santa Catarina, southern Brazil: A retrospective analysis,” Travel Medicine and Infectious Disease 41:102005 (May-Jun., 2021).

28

Didier Raoult et al, “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,” International Journal of Antimicrobial Agents 97 (Jul 2020): 396–403.

29

Roland Derwand, Martin Scholz, and Vladimir Zelenko, “COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study,” International Journal of Antimicrobial Agents 56(6):106214 (Dec 2020).

30

Harvey A. Risch, “Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis,” American Journal Of Epidemiology 189 no. 11 (Nov. 2, 2020):1218-1226.